Published May 16, 2022
- CADTH recommends that Retevmo be reimbursed by public drug plans for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), if certain conditions are met.
- Retevmo should only be covered to treat adult patients 18 years and older with metastatic RET fusion-positive NSCLC who had never received any cancer treatment or who had prior cancer treatment.
- Retevmo should only be reimbursed if prescribed by a clinician with expertise in the management of NSCLC and if the cost of Retevmo is reduced. Retevmo should not be given or reimbursed in combination with cancer treatment.